Orocidin and Syngene Forge Alliance to Propel Biotech Innovation and GMP Peptide Development

Orocidin A/S, wholly owned subsidiary of Nordicus Partners (OTCQB: NORD), has entered into a strategic partnership with Syngene International to advance GMP peptide development pipelines. The two firms will focus on the development of Orocidin's QR-01, leveraging Syngene's scalable and cost-efficient manufacturing to reduce lead times. Syngene's facilities will provide access to skilled scientists and state-of-the-art facilities, ensuring a robust supply chain for future commercialization.

Allan Wehnert, Orocidin CEO & Founder, was impressed by Syngene's professionalism and commitment to scientific excellence. Alex Del Priore, Syngene Senior Vice President, added that Syngene is well-placed to help biotech companies like Orocidin bring new drugs to market faster and more reliably.

Nordicus Partners is dedicated to supporting Nordic and U.S. life sciences companies to increase their activities in the U.S. market

Source: globenewswire